New split-dose chemo aims to help elderly lymphoma patients
NCT ID NCT03943901
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a modified schedule of standard chemotherapy (R-CHOP) for people aged 75 and older with diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. Twenty-seven participants will receive the split-dose regimen and be followed for about 2.5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with pegfilgrastim
What this could lead to
If successful, this split-dose schedule could offer a better-tolerated treatment option for older adults with DLBCL, potentially improving response rates and quality of life.
What could go wrong
This is a small, early-phase (phase II) study with only 27 participants, so results may not apply broadly. Chemotherapy side effects remain a risk, and the split-dose approach may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53705, United States